Clinical trials: psoriasis
Hidradenitis Suppurativa, Palmoplantar Pustulosis
Safety and Pharmacokinetics of Repeat Doses of CSL324 in Subjects With Hidradenitis Suppurativa and Palmoplantar Pustulosis
Study CSL324_1002 will investigate the safety and pharmacokinetics of repeat doses of CSL324 in subjects with hidradenitis suppurativa and palmoplantar pustulosis.
- Trial name
- NCT03972280
- Testing
- Recombinant anti-granulocyte colony-stimulating factor (G-CSF) receptor monoclonal antibody
- Where
- 11 sites in Australia, Denmark and 1 more
- Volunteers
- 39 people
- Sponsor
- CSL Behring
Moderate to Severe Plaque Psoriasis
P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis
The purpose of this study is to assess the safety and efficacy of brodalumab at two different doses
- Trial name
- AMAGINE-2 (NCT01708603)
- Testing
- 210 mg brodalumab, 140 mg brodalumab, ustekinumab
- Where
- 153 sites in United States, Australia and 9 more
- Volunteers
- 1,831 people
- Sponsor
- Bausch Health Americas, Inc.
Psoriasis
Study to Evaluate Psoriasis Severity and Its Psychosocial Impact Using the Simplified Psoriasis Index (SPI), as Well as Long-term Safety, Tolerability and Efficacy of Secukinumab Administered Subcutaneously in Patients With Moderate to Severe Psoriasis
Evaluate psoriasis severity and its psychosocial impact using a novel Patient Reported Outcome (the Simplified Psoriasis Index SPI) at 16 weeks, as well as long-term safety, tolerability and efficacy of secukinumab administered…
- Trial name
- IPSI-PSO (NCT02595970)
- Testing
- Secukinumab
- Where
- 17 sites in France
- Volunteers
- 120 people
- Sponsor
- Novartis Pharmaceuticals
Arthritis, Psoriatic, Psoriasis
Study Evaluating The Prevalence Of Undiagnosed Psoriatic Arthritis In Patients With Plaque Psoriasis
This study aims to collect Australian data on the prevalence of undiagnosed psoriatic arthritis in patients with plaque psoriasis.
- Trial name
- NCT00998829
- Testing
- questionnaire
- Where
- 9 sites in Australia
- Volunteers
- 458 people
- Sponsor
- Pfizer
Acne, Atopic Dermatitis
Use of the SpiderMass for in Vivo Analysis of the Skin in Five Chronic Inflammatory Dermatosis
The physiological states of the skin are characterized by a certain homeostasis linked to the balance of the metabolic pathways. When these pathways are deregulated, the proteic, lipidic and metabolic is affected.
- Conditions
- Acne, Atopic Dermatitis, Psoriasis Vulgaris, Rosacea
- Trial name
- NCT04472546
- Testing
- in-vivo mesure, Scotch, Lipid index
- Where
- France
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Pierre Fabre Dermo Cosmetique
Psoriasis
Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy
Psoriasis (PsO) is a chronic disease characterized by marked inflammation of the skin that results in thick, red, scaly plaques.
- Trial name
- NCT04908475
- Testing
- Risankizumab, Apremilast
- Where
- 54 sites in United States, Canada and 3 more
- Volunteers
- 352 people
- Sponsor
- AbbVie
Plaque Psoriasis
A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
The main aim of this study is to see how well the medicine zasocitinib works, how safe it is, and how children and teenagers aged 4 to under 18 with moderate-to-severe plaque psoriasis respond to it.
- Trial name
- NCT07250802
- Testing
- Zasocitinib
- Where
- 39 sites in United States, China and 5 more
- Volunteers
- 110 people
- Sponsor
- Takeda
Psoriasis
An Open-label, Non-controlled Study of KHK4827 in Subjects With Psoriasis
This study is an open-label, non-controlled study to evaluate the efficacy and safety of KHK4827 in subjects with pustular psoriasis (generalized) and psoriatic erythroderma. Pharmacokinetics of KHK4827 will also be assessed.
- Trial name
- NCT01782937
- Testing
- KHK4827
- Where
- Japan
- Volunteers
- 30 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Psoriasis
A Clinical Trial of TQH3906 Capsules in Healthy Volunteers
This study was divided into three parts: single and multiple dosing and food effect study, which were designed to evaluate the safety and tolerability of TQH3906 capsules administered in single or multiple dose escalation in…
- Trial name
- NCT06230588
- Testing
- TQH3906 capsule
- Where
- China
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Psoriatic Arthritis, Axial Spondyloarthritis
Study of Efficacy and Safety of Secukinumab in Psoriatic Arthritis and Axial Spondyloarthritis Patients With Active Enthesitis Including One Achilles Tendon Site
The purpose of this study was to demonstrate efficacy, including effects on inflammation by magnetic resonance imaging (MRI) assessments, of secukinumab on Achilles tendon enthesitis for up to 1 year with a primary focus at Week…
- Conditions
- Psoriatic Arthritis, Axial Spondyloarthritis, Enthesitis
- Trial name
- ACHILLES (NCT02771210)
- Testing
- Secukinumab
- Where
- 55 sites in Bulgaria, Czechia and 6 more
- Volunteers
- 204 people
- Sponsor
- Novartis Pharmaceuticals
Palmoplantar Pustular Psoriasis
Palmoplantar Pustular Psoriasis Efficacy and Safety With Secukinumab
A one year study assessing the efficacy and safety of secukinumab compared with placebo in adult patients with moderate to severe palmoplantar pustular psoriasis - amended with an optional extension treatment period of up to a…
- Trial name
- NCT02008890
- Testing
- Secukinumab 300mg, Secukinumab 150mg
- Where
- 68 sites in Austria, Belgium and 8 more
- Volunteers
- 237 people
- Sponsor
- Novartis Pharmaceuticals
Plaque Psoriasis Patients
An Phase III Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With PsO
The purpose of this study is to examin the efficacy and safety of the study drug recombinant anti-IL-17A humanized monoclonal antibody in Chinese participants with moderate-to-severe plaque psoriasis.
- Trial name
- NCT06299982
- Testing
- 608 Q2W, 608 Q4W
- Volunteers
- 750 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Psoriasis
Safety and Efficacy Study of A Novel Ointment to Treat Plaque Type Psoriasis
The purpose of this study is to evaluate the safety and efficacy of AN2728 Ointment, 5%, compared to Ointment Vehicle, applied twice daily for 12 weeks, in the treatment of plaque type psoriasis
- Trial name
- NCT00755196
- Testing
- AN2728, Ointment vehicle
- Where
- Mexico
- Volunteers
- 30 people
- Sponsor
- Pfizer
Plaque Psoriasis
Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
The objective of the study is to evaluate the safety and efficacy of a topical lotion.
- Trial name
- NCT02462070
- Testing
- IDP-118 Lotion, IDP-118 Vehicle Lotion
- Where
- 16 sites in United States
- Volunteers
- 203 people
- Sponsor
- Bausch Health Americas, Inc.
Psoriasis
Topical CP-690,550 For Chronic Plaque Psoriasis
Study will test effectiveness of an experimental drug applied once or twice daily to two psoriasis plaques. Requires 1 clinic visit each week for 5 weeks.
- Trial name
- NCT00678561
- Testing
- CP-690,550
- Where
- 20 sites in United States, Canada
- Volunteers
- 81 people
- Sponsor
- Pfizer
Psoriasis (PsO)
A Drug-Drug Interaction Study Between HS-10374 Tablets and Drospirenone and Ethinyl Estradiol Tablets(Yasmin®)
This trial is a single-center, open-label, fixed-sequence, self-controlled clinical study to evaluate Drug-Drug Interaction Between HS-10374 Tablets and Drospirenone and Ethinyl Estradiol Tablets (Yasmin®)
- Trial name
- NCT07181343
- Testing
- HS-10374 tablets, Drospirenone and Ethinyl Estradiol tablets
- Where
- China
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Hansoh BioMedical R&D Company
Psoriasis
Pharmacokinetic, Safety and Immunogenicity Study of New Process CMAB015 and Cosentyx in Healthy Volunteers
This is a randomized, double-blinded, controlled Phase I study of new process CMAB015 administered by subcutaneous injection. This study will characterize the pharmacokinetic, safety and immunogenicity of new process CMAB015…
- Trial name
- NCT07254325
- Testing
- Secukinumab 150mg s.c.
- Where
- China
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Taizhou Mabtech Pharmaceutical Co.,Ltd
Psoriasis
A Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis
The study is comprised of two parts. The first portion of this study will be a double-blind, Sponsor-unblinded, vehicle-controlled study with application of ruxolitinib or vehicle to paired lesions at least 15 cm apart in…
- Trial name
- NCT00820950
- Testing
- Ruxolitinib phosphate cream, Dovonex® calcipotriene 0.005%, Diprolene® AF betamethasone dipropionate 0.05% cream.
- Where
- 6 sites in United States
- Volunteers
- 29 people
- Sponsor
- Incyte Corporation
Plaque Psoriasis
A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis Subjects
This is a multi-center, randomized, investigator-blinded, calcipotriol and betamethasone dipropionate gel and vehicle-controlled phase 3 clinical study to evaluate the efficacy and safety of MC2-01 cream in the treatment of…
- Trial name
- NCT07357831
- Testing
- MC2-01 cream, MC2-01 vehicle, CAL/BDP Gel
- Where
- 55 sites in China
- Volunteers
- 539 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Psoriatic Arthritis
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs
The purpose of this study is to evaluate the efficacy and safety of deucravacitinib versus placebo in participants with active psoriatic arthritis who are naïve to biologic disease-modifying anti-rheumatic drugs.
- Trial name
- NCT04908202
- Testing
- Deucravacitinib
- Where
- 183 sites in United States, Argentina and 19 more
- Volunteers
- 670 people
- Sponsor
- Bristol-Myers Squibb
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.